March 23 (Reuters) – Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines in a deal worth up to $2.18 billion.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal
Peoria, IL, USA
50 °F Sunny
Comments